PsiOxus Therapeutics Initiates 'OCTAVE' Ovarian Cancer Study for Oncolytic Vaccine Enadenotucirev
OXFORD, England, Jun 17, 2014 (BUSINESS WIRE) -- PsiOxus Therapeutics Ltd. (PsiOxus), an award-winning biotechnology company developing innovative new treatments for cancer, today announced the first dosing of a patient in the OCTAVE ( O varian C ancer T reated with A deno V accine E nadenotucirev) study. OCTAVE is a phase I/II clinical trial to assess the safety and efficacy of its oncolytic vaccine enadenotucirev () ColoAd1 ) in platinum-resistant ovarian cancer patients at multiple UK cancer centres beginning this month. Enadenotucirev has shown potent, broad-spectrum, anti-cancer activity pre-clinically and is also in phase I/II clinical trials in patients with colorectal tumours.
The OCTAVE study will examine the safety, tolerability, pharmacokinetics and efficacy of administering the vaccine directly into the abdomen of cancer patients, where ovarian cancer tends to recur (a process known as intra-peritoneal or IP delivery). The phase I component of the study will determine the dose of enadenotucirev to be used alone or in combination with paclitaxel. The phase II component will be an open label dose expansion of the combination regimen of enadenotucirev and paclitaxel to determine whether this combination has a risk benefit profile that supports further investigation in the treatment of patients with platinum-resistant epithelial ovarian cancer.
Dr Iain McNeish, MD, Professor of Gynaecological Oncology at the Institute of Cancer Sciences at the University of Glasgow, is the principal investigator of the OCTAVE study. The trial is co-funded by a £1.7 million grant awarded to PsiOxus by the UK government-backed Biomedical Catalyst. This programme is designed to deliver growth to the UK life sciences sector and run jointly by the UK's innovation agency, the Technology Strategy Board, and the Medical Research Council.
PsiOxus CEO Dr John Beadle commented: "Our enadenotucirev oncolytic vaccine has enormous potential to treat a broad spectrum of solid cancer types and starting this OCTAVE study is a key milestone as we progress towards demonstrating its effectiveness in a second form of cancer with a very significant unmet medical need."
Enadenotucirev was originally developed using a directed evolution process, with the aim of generating an entirely novel virus with optimised cancer-lytic properties. It has been shown to have little or no activity in normal cells whilst keeping a very high level of anti-cancer potency. As well as assessing how effective intraperitoneal enadenotucirev is for treating ovarian cancer, PsiOxus is also carrying out clinical studies evaluating its safety and efficacy via intravenous injection in patients with colorectal cancer. The phase I/II EVOLVE study ( EV aluating O nco L ytic V accine E fficacy) is currently underway and has shown some promising early results.
About PsiOxus Therapeutics, Ltd.
PsiOxus Therapeutics is an Oxford, UK-based development stage biotechnology company using non-traditional approaches to develop novel therapeutics that address cancer and other clinically unmet diseases. Enadenotucirev is an oncolytic vaccine for the systemic treatment of metastatic cancer, which has demonstrated exceptional anti-cancer properties in late pre-clinical development and is now in phase II clinical development. MT-102 is a dual action Anabolic Catabolic Transforming Agent (ACTA) in phase II clinical development for the treatment of cachexia and sarcopenia. The Company is also developing the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines.
Dr John Beadle is CEO of PsiOxus. He was previously a co-founder of PowderMed, which was sold to Pfizer, Inc. in 2006 for more than $300 million. Dr Michael Moore, the former CEO of Piramed, which was acquired by Roche in 2008, serves as Chairman of the Board of Directors.
About the Biomedical Catalyst
The £180 million Biomedical Catalyst is an integrated translational funding programme jointly operated by the Medical Research Council and the Technology Strategy Board providing responsive and effective support for the best life science opportunities arising in the UK. Support through the Biomedical Catalyst is available to academics and UK SMEs looking to develop innovative solutions to healthcare challenges either individually or in collaboration.
SOURCE: PsiOxus Therapeutics, Ltd.
Dr John Beadle, Chief Executive Officer
Tel: +44 (0) 7810 770 310
US Media Enquiries:
Erik Clausen, Chempetitive Group
Tel: +1 781-608-7091
UK Media Enquiries:
Dr Paul Avery, BioStrata
Tel: +44(0)1223 828202
Copyright Business Wire 2014